StockIQpro
NASDAQ:RARE

Ultragenyx Pharmaceutical Inc.

Track all markets on TradingView
Track all markets on TradingView

Ultragenyx Pharmaceutical Inc.'s revenue grew 20.2% in fiscal 2025 to $673.0M while operating margin rose to −79.5%, its highest in 10 years. Free cash flow was −$472.0M, −70.1% of revenue, and the diluted share count rose 9.0%.Summary generated from Ultragenyx Pharmaceutical Inc.'s SEC filings. Latest annual report filed Feb 18, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$673.0M
Revenue growth+20.2%
Revenue, 5-yr CAGR+19.9%
Gross marginn/a
Operating margin−79.5%
Net margin−85.4%
ROICn/a
Return on equity−657.1%
Debt / equityn/a
Free cash flow−$472.0M
FCF margin−70.1%
Share count change+9.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue351363434560673
Operating income−382−649−569−536−535
Net income−454−707−607−569−575
Free cash flow−412−497−519−421−472

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations